Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy. (Q48030719)
Jump to navigation
Jump to search
scientific article published on 31 May 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy. |
scientific article published on 31 May 2017 |
Statements
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy (English)
Shaopeng Chen
Qinsheng Sun
Ning Wang
Dan Li
Shuangshuang Miao
Chunmei Gao
Yuzong Chen
Chunyan Tan